Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
Holding EPRX?
Track your performance easily

Eupraxia Pharmaceuticals (EPRX) Income Statement

2 Followers

Eupraxia Pharmaceuticals Income Statement

Last quarter (Q2 2024), Eupraxia Pharmaceuticals's total revenue was C$―, a decrease of ― from the same quarter last year. In Q2, Eupraxia Pharmaceuticals's net income was C$-6.01M. See Eupraxia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
-----
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
C$ 28.64MC$ 27.95MC$ 23.62MC$ 18.68MC$ 2.25M
Operating Income
C$ -28.64MC$ -27.95MC$ -23.62MC$ -18.68MC$ -2.25M
Net Non Operating Interest Income Expense
C$ 372.22KC$ -307.20KC$ -1.02MC$ 1.23MC$ 1.88M
Other Income Expense
C$ -352.48KC$ 738.58KC$ -412.44KC$ -3.46MC$ 116.76K
Pretax Income
C$ -28.11MC$ -28.93MC$ -23.92MC$ -23.37MC$ -4.01M
Tax Provision
C$ 36.42KC$ 36.42K---
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
C$ -27.48MC$ -28.22MC$ -23.26MC$ -22.99MC$ -4.00M
Basic EPS
C$ -0.90C$ -1.17C$ -1.24C$ -1.88C$ -0.31
Diluted EPS
C$ -0.90C$ -1.17C$ -1.24C$ -1.88C$ -0.31
Basic Average Shares
C$ 117.31MC$ 24.15MC$ 19.29MC$ 12.41MC$ 12.87M
Diluted Average Shares
C$ 117.31MC$ 24.15MC$ 19.29MC$ 12.41MC$ 12.87M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
C$ 28.64MC$ 27.95MC$ 23.62MC$ -18.68MC$ -2.25M
Net Income From Continuing And Discontinued Operation
C$ -27.48MC$ -28.22MC$ -23.26MC$ -22.99MC$ -4.00M
Normalized Income
C$ -23.85MC$ -21.26MC$ -17.57MC$ -17.18MC$ -2.82M
Interest Expense
-----
EBIT
C$ -27.40MC$ -27.76MC$ -22.33MC$ -22.07MC$ -2.13M
EBITDA
C$ -27.27MC$ -27.60MC$ -22.14MC$ -21.96MC$ -2.01M
Currency in CAD

Eupraxia Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis